Novartis has agreed to buy all remaining rights to Ofatumumab from Britain’s GlaxoSmithKline for up to $1 billion, boosting the Swiss drugmaker’s stable of multiple sclerosis (MS) treatments.
Basel-based Novartis had previously acquired the rights to Ofatumumab for oncology indications, but it is currently being developed for relapsing remitting multiple sclerosis and other auto-immune conditions.
{iframe}http://www.cnbc.com/2015/08/21/novartis-buys-remaining-rights-to-gsk-treatment-in-deal-up-to-1b.html{/iframe}